arrow
E

Elena Lorenzi

irccs fondazione del piemonte per l'oncologia
H指数:20
被引数:1,415

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram

使用新颖且外部验证的预后列线图,为下一代免疫治疗早期临床试验优化患者选择

2024-01-150
OAAI
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
2022-10-2812
OAAI
Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes
2021-11-132
OAAI
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing

70岁新诊断的胶质母细胞瘤患者年龄大于65岁?倾向得分平衡的匹配病例对照研究中两类结果的评价

2021-03-012
PREAI
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series

IDH状态是预测新诊断的间变性胶质瘤患者预后的唯一因素吗?单机构大型系列的结果评估和预后因素分析

2020-09-017
OA
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

培美曲塞和卡铂联合贝伐单抗作为恶性胸膜间皮瘤一线治疗的II期研究

2013-07-1674
OA
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
2013-03-0116
PREAI